These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 30762880)

  • 21. Cytotoxic effect of CLL‑1 CAR‑T cell immunotherapy with PD‑1 silencing on relapsed/refractory acute myeloid leukemia.
    Lin G; Zhang Y; Yu L; Wu D
    Mol Med Rep; 2021 Mar; 23(3):. PubMed ID: 33495835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Generation of Suicide Gene-Modified Chimeric Antigen Receptor-Redirected T-Cells for Cancer Immunotherapy.
    Minagawa K; Al-Obaidi M; Di Stasi A
    Methods Mol Biol; 2019; 1895():57-73. PubMed ID: 30539529
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Novel T-Cell Engaging Bi-specific Antibody Targeting the Leukemia Antigen PR1/HLA-A2.
    Herrmann AC; Im JS; Pareek S; Ruiz-Vasquez W; Lu S; Sergeeva A; Mehrens J; He H; Alatrash G; Sukhumalchandra P; St John L; Clise-Dwyer K; Zha D; Molldrem JJ
    Front Immunol; 2018; 9():3153. PubMed ID: 30713535
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia.
    Kenderian SS; Ruella M; Shestova O; Klichinsky M; Aikawa V; Morrissette JJ; Scholler J; Song D; Porter DL; Carroll M; June CH; Gill S
    Leukemia; 2015 Aug; 29(8):1637-47. PubMed ID: 25721896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute myeloid leukemia and novel biological treatments: monoclonal antibodies and cell-based gene-modified immune effectors.
    Tettamanti S; Magnani CF; Biondi A; Biagi E
    Immunol Lett; 2013; 155(1-2):43-6. PubMed ID: 24076117
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia.
    Anguille S; Van Tendeloo VF; Berneman ZN
    Leukemia; 2012 Oct; 26(10):2186-96. PubMed ID: 22652755
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD123 redirected multiple virus-specific T cells for acute myeloid leukemia.
    Zhou L; Liu X; Wang X; Sun Z; Song XT
    Leuk Res; 2016 Feb; 41():76-84. PubMed ID: 26740053
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cellular therapy for acute myeloid Leukemia - Current status and future prospects.
    Hansrivijit P; Gale RP; Barrett J; Ciurea SO
    Blood Rev; 2019 Sep; 37():100578. PubMed ID: 31109711
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for the Targeting of Acute Myeloid Leukemia.
    Arcangeli S; Rotiroti MC; Bardelli M; Simonelli L; Magnani CF; Biondi A; Biagi E; Tettamanti S; Varani L
    Mol Ther; 2017 Aug; 25(8):1933-1945. PubMed ID: 28479045
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute Myeloid Leukemia Targeting by Chimeric Antigen Receptor T Cells: Bridging the Gap from Preclinical Modeling to Human Studies.
    Rotiroti MC; Arcangeli S; Casucci M; Perriello V; Bondanza A; Biondi A; Tettamanti S; Biagi E
    Hum Gene Ther; 2017 Mar; 28(3):231-241. PubMed ID: 27967241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward.
    Li J; Li W; Huang K; Zhang Y; Kupfer G; Zhao Q
    J Hematol Oncol; 2018 Feb; 11(1):22. PubMed ID: 29433552
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment.
    Isidori A; Salvestrini V; Ciciarello M; Loscocco F; Visani G; Parisi S; Lecciso M; Ocadlikova D; Rossi L; Gabucci E; Clissa C; Curti A
    Expert Rev Hematol; 2014 Dec; 7(6):807-18. PubMed ID: 25227702
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective.
    Han C; Kwon BS
    Immunotherapy; 2018 Mar; 10(3):221-234. PubMed ID: 29370727
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Not Available].
    Rahal I; Cabannes-Hamy A; Boissel N
    Bull Cancer; 2018 Dec; 105 Suppl 2():S158-S167. PubMed ID: 30686354
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
    Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
    J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CAR-T cell therapy in melanoma: A future success story?
    Simon B; Uslu U
    Exp Dermatol; 2018 Dec; 27(12):1315-1321. PubMed ID: 30288790
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute Myeloid Leukemia Cells Express ICOS Ligand to Promote the Expansion of Regulatory T Cells.
    Han Y; Dong Y; Yang Q; Xu W; Jiang S; Yu Z; Yu K; Zhang S
    Front Immunol; 2018; 9():2227. PubMed ID: 30319662
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML.
    Perna F; Berman SH; Soni RK; Mansilla-Soto J; Eyquem J; Hamieh M; Hendrickson RC; Brennan CW; Sadelain M
    Cancer Cell; 2017 Oct; 32(4):506-519.e5. PubMed ID: 29017060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapy in acute myeloid leukemia.
    Arpinati M; Curti A
    Immunotherapy; 2014; 6(1):95-106. PubMed ID: 24341888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.